Attitudes towards and use of point-of-care tests for STIs: results from a survey of STI conference attendees in 2023
- PMID: 40460248
- PMCID: PMC12414539
- DOI: 10.1071/SH25003
Attitudes towards and use of point-of-care tests for STIs: results from a survey of STI conference attendees in 2023
Abstract
Background Point-of-care tests (POCTs) for sexually transmitted infections (STIs) have become increasingly available since the COVID-19 pandemic. There is limited data on the use of these tests in clinical practice as well as the potential challenges to integrating them into care. Methods We conducted a survey of participants at an international STI conference in July 2023 to better understand the use of STI POCTs. Results A total of 83% of respondents reported using traditional POCTs (such as Gram stain and wet prep) in their practices, and 52% used newer POCTs (most commonly: rapid tests for Treponema pallidum (26%) and molecular tests for Neisseria gonorrhoeae /Chlamydia trachomatis (26%)). Newer POCTs were commonly used for symptomatic (77%) and asymptomatic patients (46%), in addition to asymptomatic contacts of people with STIs (51%) and those with increased vulnerabilities (47%). Disclosure of results from newer POCTs occurred during the clinic visit for the majority of respondents (71%). When asked about the most important obstacles to using newer POCTs, cost of the test to the clinical practice or healthcare system was the most cited issue (43%), whereas concerns regarding changing or establishing new clinic workflows was the second most cited issue (23%). Most participants were 'definitely' (58%) or 'maybe' (29%) in favor of patient self-tests; however, top concerns included lack of follow-up to ensure counseling/appropriate treatment for the patient and their partner. Conclusions To meaningfully adopt newer STI POCTs, further research is needed to understand practice patterns and barriers to implementation.
Conflict of interest statement
YM, CAG receive funds from Binx, Health. MH has received speaker fees and donation of research kits to Johns Hopkins University from Cepheid and Roche Diagnostics and receives royalties from UpToDate. ST has been a consultant for Biofire Diagnostics, Roche Molecular Diagnostics and Luca Biologics, receives royalties from UpToDate and has received speaker honoraria from Roche Molecular Diagnostics and Medscape/WebMD. She participates in research supported by in-kind donation of test kits from Hologic. Y-HH, HS, GY, and AR do not have any conflicts of interest to report.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous